Redalpine backs CHF 6m funding round for Lunaphore

Zühlke Ventures, Polytech Ecosystem Ventures and Occident Group also invested in the round, along with unnamed private investors.

The company said it chose new investor Zühlke for its industrial expertise and Polytech for its Silicon Valley presence.

Redalpine drew equity from its second fund RAC II to support the investment. The vehicle closed on CHF 60m in July 2013 and reported a net IRR of 33% as of December 2016, according to unquote" data.

The fresh capital will be used to pave the way for market access.

Previous funding
In April 2015, Redalpine led a CHF 2m series-A round for Lunaphore alongside private investors.

Company
Established in 2014, Lunaphore has developed a tissue diagnostics platform for the analysis and classification of tumours. It builds devices that it says can significantly shorten the time of cancer diagnostics assays with higher precision.

The company is headquartered in Lausanne, Switzerland. To date, the company has published three clinical studies with more than 100 patient cases.

People
Redalpine – Michael Sidler (partner).
Lunaphore – Ata Tuna Ciftlik (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Switzerland
• Venture